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Abstract
Objectives. The DETECT algorithm has been developed to identify SSc patients at risk for pulmonary arterial hyper-
tension (PAH) yielding high sensitivity but low specificity, and positive predictive value. We tested whether cardiopul-
monary exercise testing (CPET) could improve the performance of the DETECT screening strategy.
Methods. Consecutive SSc patients over a 30-month period were screened with the DETECT algorithm and positive
subjects were referred for CPET before the execution of right-heart catheterization. The predictive performance of CPET
on top of DETECT was evaluated and internally validated via bootstrap replicates.
Results. Out of 314 patients, 96 satisfied the DETECT application criteria and 54 were positive. PAH was ascertained in
17 (31.5%) and pre-capillary pulmonary hypertension in 23 (42.6%) patients. Within CPET variables, the slope of the
minute ventilation to carbon dioxide production relationship (VE/VCO2 slope) had the best performance to predict PAH at
right-heart catheterization [median (interquartile range) of specificity 0.778 (0.7140.846), positive predictive value 0.636
(0.5560.750)]; exploratory analysis on pre-capillary yielded a specificity of 0.714 (0.6360.8) and positive predictive value
of 0.714 (0.6360.8).
Conclusion. In association with the DETECT algorithm, CPET may be considered as a useful tool in the workup of SSc-
related pulmonary hypertension. The sequential determination of the VE/VCO2 slope in DETECT-positive subjects may
reduce the number of unnecessary invasive procedures without any loss in the capability to capture PAH. This strategy
had also a remarkable performance in highlighting the presence of pre-capillary pulmonary hypertension.
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Rheumatology key messages
. Early detection of pulmonary arterial hypertension in SSc positively influences prognosis.
. The screening strategy for pulmonary arterial hypertension or haemodynamic pulmonary hypertension with
DETECT is suboptimal.
. Cardiopulmonary exercise testing improves DETECT’s performance in the screening for pulmonary arterial
hypertension.
Introduction
Pulmonary arterial hypertension (PAH) is a progressive dis-
ease affecting the pre-capillary pulmonary vascular bed,
leading to an increase in pulmonary vascular resistance,
right ventricular failure and death [1]. SSc is one of the
main conditions associated with PAH, with a prevalence
ranging from 5 to 12% [1]. Despite an optimized treatment,
PAH is still a relevant cause of death in SSc, with an esti-
mated 3-year survival rate no higher than 52% [2].
Recent evidence indicates that an early diagnosis and
treatment are the most relevant factors to improve the
1Scleroderma Unit, Referral Center for Systemic Autoimmune
Diseases, 2Cardiovascular Diseases Unit, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico di Milano, Milan, 3Department
of Clinical Sciences and Community Health, University of Milan, Milan
and 4Division of Rheumatology and Clinical Immunology, Humanitas
Research Hospital, Rozzano, Italy
*Alessandro Santaniello and Rosa Casella contributed equally to this
study.
Correspondence to: Lorenzo Beretta, Scleroderma Unit, Referral
Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico di Milano, Via Pace 9, 20122,
Milan, Italy. E-mail: lorberimm@hotmail.com
Submitted 26 March 2019; accepted 11 September 2019
! The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use,






















niversità degli Studi di M
ilano user on 23 O
ctober 2019
prognosis and to reduce the mortality secondary to SSc-
PAH [3, 4], thus a structured screening of PAH is highly
recommended in SSc. However, an early diagnosis of
SSc-PAH is difficult because of the absence of specific
biomarkers and the presence of several non-specific
symptoms confounding the clinical assessment [1, 5, 6].
In 2014 the first evidence-based screening algorithm for
SSc-PAH (DETECT) was published [6], in which the false-
negative rate was determined by performing right-heart
catheterization (RHC) in all patients. The DETECT algo-
rithm showed a remarkably high sensitivity (96%) and
negative predictive value (NPV) (98%) in diagnosing
SSc-PAH, outperforming the European Society of
Cardiology/European Respiratory Society (ESC/ERS)
screening approach, and thus reducing the rate of
missed diagnoses [6, 7]. However, DETECT had a low
specificity (48%) and positive predictive value (PPV)
(35%), and resulted in a high proportion of unnecessary
RHC procedures (65%).
Cardiopulmonary exercise testing (CPET) proved a
useful tool in the diagnosis of cardiopulmonary diseases,
including PAH. A recent study showed that abnormalities
in gas exchange during exercise seem to be correlated to
pulmonary vascular disease in SSc [8].
We thus hypothesize that CPET might improve PAH
screening procedures, allowing a reduction of the
number of unnecessary RHCs and better highlighting the
occurrence of treatable forms of pulmonary hypertension
(PH) [3, 4]. To test this hypothesis, we sequentially
coupled CPET with the DETECT screening algorithm,
looking for functional parameters that may help to in-
crease its PPV while avoiding dampening its sensitivity.
Methods
Patients and procedures
Consecutive adult SSc patients referred to our institutions
were screened between June 2017 and February 2019
according the DETECT criteria: (i) diagnosis of SSc ac-
cording to the ACR [9], (ii) predicted diffusing capacity
for carbon monoxide <60% of predicted and (iii) disease
duration >3 years from first non-Raynaud symptom.
Pulmonary function tests and blood samples were per-
formed according to the DETECT approach [6]. Doppler
echocardiography along with CPET were performed by
experienced cardiologists (M.V., I.R.). All RHCs were per-
formed by single operator. Echocardiography and CPET
were separately analysed by two trained clinicians (R.C.
and I.R.); discordant results were solved by convergence.
CPET was performed on a stationary cycle ergometer
with an incremental work rate between 5 and 15 W/min up
to the patients’ maximum tolerance, followed by 3 min of
recovery. The exercise protocol was selected according
to the patient’s exercise capacity to aim for 812 min in
length. Gas exchange was measured breath-by-breath
during the test, using calibrated COSMED Quark-B2
CPX equipment (COSMED, Rome, Italy). The first ventila-
tory threshold (fVT) was determined from gas exchange by
the V-slope method, derived from a plot with VO2 (x-axis)
and VCO2 (y-axis) on equal axis scaling, and was recog-
nized as the point where VCO2 started increasing faster
than VO2. The gradient of the relationship between minute
ventilation (VE) and carbon dioxide production (VCO2) (VE/
VCO2 slope) was calculated by linear regression analysis
using data acquired from the whole test [10].
Following DETECT indications, patients underwent RHC
performed according to current recommendations [11].
Every single pressure curve was manually analysed at
the end of RHC to avoid potential errors from automatic
reading. PAH was defined as the presence of a mean pul-
monary artery pressure 525 mmHg at rest with a with a
pulmonary artery wedge pressure 415 mmHg and pul-
monary vascular resistances 5 3 Wood units. These def-
initions were used in the original DETECT paper and to
tune the screening algorithm [6]. Besides these definitions
and according to the haemodynamic definition recently
proposed by the 6th World Symposium on Pulmonary
Hypertension task force, we also classified patients with
pre-capillary PH as those with mean pulmonary artery
pressure >20 mmHg, pulmonary vascular resistance 53
Wood units and pulmonary artery wedge pressure
415 mmHg [12].
All patients signed written consent for the study, which
was approved by the local ethics committee (Comitato
Etico Area 2) with number 265_2016bis and subsequent
modification (21 June 2017).
Statistical analysis
Continuous variables were compared either by the
Student’s t test or the MannWhitney U test if normally
or non-normally distributed, respectively. Categorical vari-
ables were compared by means of Fisher’s exact test.
A bootstrap aggregating (bagging) procedure was used
to determine and validate the performance of CPET in
DETECT-positive patients. To this end, 50 000 bootstrap
samples with replacement were generated; for each CPET
variable in each bootstrap sample, we chose the threshold
that maximized the sensitivity to capture PAH; the chosen
threshold was then tested in the out-of-bag samples.
Median and interquartile ranges of out-of-bag results are
presented. The optimal target of CPET as a screening tool
should be a sensitivity equal to 1 (100%), that is the cap-
ability of not spoiling the NPV of DETECT; a count of
models/variables with perfect sensitivity is then performed
to provide an estimate of the goodness of the sequential
use of CPET in DETECT-positive patients. Albeit the
sensitivity and NPV of DETECT in the context of pre-
capillary PH is undetermined, we used the same criterion
to determine the performance of CPET in capturing pre-
capillary PH.
Results
Overall, 314 SSc patients were screened. Ninety-six were
considered at risk according to DETECT entry criteria; of
these, 76 passed the DETECT step 1 and 54 the step 2,
and were thus referred for CPET and RHC. Twenty-three
patients (42.6%) had pre-capillary PH according to the
new proposed haemodynamic criteria [12], including 17
2 https://academic.oup.com/rheumatology
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with PAH (31.5%) according to the ESC/ERS 2015
guidelines (Fig. 1) [1]. Additionally we identified three
post-capillary PH (5.5%). In our cohort, seven patients
had signs of interstitial lung disease at high-resolution
CT. Interstitial lung disease extension was mild in four
cases (<10% of lung parenchyma) and intermediate in
three (1020% of lung parenchyma). In the absence of
extensive interstitial lung disease, no patient could be as-
signed to group 3 PH [1]. Clinical, demographic, haemo-
dynamic, CPET and echocardiographic characteristics of
the patients are reported in Table 1.
We did not find significant differences in demographical
and echocardiographic data between the PAH and non-
PAH groups, or between those with or without pre-capil-
lary PH (Table 1).
After bagging validation, two CPET variables had the
best performance in assessing PAH. The VE/VCO2 at
the fVT (VE/VCO2@fVT) had sensitivity equal to 1.0 in
63% of models, with a median sensitivity of 1.0
(0.8571.0), specificity of 0.833 (0.7690.882), PPV of
0.7 (0.60.8) and NPV of 1.0 (0.9231.0). The VE/VCO2
slope had a sensitivity equal to 1.0 in 87% of models,
with a median sensitivity of 1.0 (1.01.0), specificity of
0.778 (0.7140.846), PPV of 0.636 (0.5560.750) and
NPV of 1.0 (1.01.0). The bootstrapped thresholds to
detect the presence of PAH were 41.2 and 39,
respectively.
When pre-capillary PH was considered, we obtained
the performance metrics reported hereafter. VE/
VCO2@fVT: sensitivity 1.0 (0.8891.0), specificity 0.455
(0.3640.556), PPV 0.571 (0.50.643) and NPV 1.0
(0.8571.0), with perfect sensitivity in 63.1% of models;
VE/VCO2 slope: sensitivity 1.0 (0.8891.0), specificity
0.714 (0.6360.8), PPV 0.714 (0.6360.8) and NPV 1.0
(0.8891.0), with maximum sensitivity in 63.7% of
models. The bootstrapped thresholds to detect the pres-
ence of pre-capillary PH were 35.5 and 36, respectively.
None of the other CPET or ecocardiographic variables
listed in Table 1 had a substantial effect on improving the
DETECT performance in capturing PAH/pre-capillary PH.
Discussion
The main finding of our study is the potential capability of
selected CPET parameters to reduce the number of refer-
rals for RHC in patients at risk for PAH. Namely, we
showed that when sequentially applied to the DETECT
screening, the measure of VE/VCO2@fVT or VE/VCO2
slope is predictive for the presence of SSc-PAH. Due to
a better technical reproducibility and higher rates of per-
fect screening fit (i.e. models with sensitivity equal to 1),
the VE/VCO2 slope seems the parameter of choice to be
used in combination with the DETECT screening algo-
rithm. Indeed, in our population this strategy and a VE/
VCO2 slope cut-off value 539 would have yielded a the-
oretical reduction in the number of RHCs from 54 to 25
without any missed diagnoses. Due to the changing def-
inition of PH we also exploratively evaluated the perform-
ance of CPET in the context of the newly proposed
haemodynamic criteria for pre-capillary PH [12]. A slightly
lower VE/VCO2 threshold (536) was found to be of use in
assessing the presence of pre-capillary PH. It is worth
noting that the DETECT screening algorithm was opti-
mized to capture SSc-PAH with a high sensitivity and
that the ‘true’ performance of DETECT in pre-capillary
PH is unknown. Theoretically, the feature selection and
validation strategy that led to the development of
DETECT [6] should be reworked altogether to tune the
algorithm to optimize its performance in pre-capillary
PH. Still, our data indicate that CPET may be useful in
the context of pre-capillary PH.
Our data on ventilatory efficiency are in accordance
with Dumitrescu et al. [8], while we could not confirm a
role for peak VO2 in screening for SSc-PAH. These differ-
ences could be due to the different selection criteria
applied, as we indeed focused on a screened population,
excluding cases with other forms of lung involvement that
may increase peak VO2 in the absence of pulmonary
vasculopathy.
Several factors may link ventilatory efficiency to pul-
monary vascular disorders. The functional assessment
and the ventilatory adaptation to effort are able to indi-
viduate the presence of pulmonary vascular remodelling
[13]. The excess in exercise-induced hyperventilation may
be explained by several factors. Firstly, we can hypothe-
size a role for the ventilation/perfusion mismatch. The in-
crease in the dead space impairs the mobilization of CO2
from blood to the airspace, forcing ventilation to increase
in the effort to eliminate metabolic CO2. In low perfusion
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states, decreased blood passing by the alveoli and lower
diffusion across the alveolararterial junction led to
exhaled gas with less CO2, that is, a low end-tidal CO2
(PetCO2@fVT) [13, 14], as we indeed observed in our SSc-
PAH/pre-capillary PH subjects. Secondly the neural reflex
pathways, influencing sympathetic activation and hyper-
ventilation, might contribute to our results. As reported
elsewhere, the degree of ventilatory inefficiency seems
to be correlated to chemosensitivity and sympathetic
activation [15, 16]. Autonomic balance alterations may
be present in SSc patients [17] and seem to be correlated
to exercise tolerance and aerobic capacity [18].
Accordingly, our results showed that SSc-PAH patients
had lower VO2 peak as well as PetCO2@fVT than those
without PAH. Impaired aerobic capacity and dysregulated
CO2 control mechanisms should be considered as indirect
signs of altered chemosensitivity and activated sympa-
thetic nervous system [19]. Finally, we may suppose that
TABLE 1 Clinical, haemodynamic and functional characteristics of participants
SSc (n=54) PAH+ (n=17) PAH (n=37) PC-PH+ (n=23) PC-PH (n=31)
Demographic and clinical data
Age, years 63.4 (12.1) 66.2 (7.6) 62.1 (13.6) 65.5 (8.3) 61.8 (14.2)
BMI, kg/m2 22.6 (4.1) 21.5 (4.2) 23.1 (3.9) 22.5 (4.7) 22.7 (3.5)
Disease duration, years 14.1 (7.1) 15.9 (7.6) 13.3 (6.8) 15.9 (7.6) 13.3 (6.8)
FVC, % 99.7 (23.9) 94.9 (18.7) 101.8 (25.9) 96.1 (19.3) 102.4 (26.8)
DLCO, % 45.7 (9.0) 40.3 (9.5)** 48.1 (7.8) 42.5 (9.5) 48.1 (8.0)
NTproBNP, ng/dl 185.0 (87.2290.0) 256 (111.6813.8) 171 (77.5268) 245.5 (124.7460.5) 153.0 (75.0259.0)
Uric acid, mg/dl 4.9 (1.3) 5.3 (1.7) 4.8 (1.1) 7.6 (3.7) 4.6 (1.1)
Females, n (%) 52 (96) 17 (100) 35 (95) 23 (100) 29 (93)
lcSSc, n (%) 44 (81) 13 (76) 31 (84) 17 (74) 27 (87)
ACA, n (%) 38 (70) 12 (71) 26 (70) 15 (65) 23 (74)
Teleangectasia, n (%) 51 (94) 15 (88) 36 (97) 21 (91) 30 (97)
Right axis deviation, n (%) 2 (4) 2 (1) 0 2 (1) 0
Haemodynamic parameters
mPAP, mmHg 22.7 (5.5) 28.8 (2.4)*** 19.9 (4.1) 27.2 (3.5)** 19.4 (4.3)
PCWP, mmHg 8.6 (3.6) 8.6 (2.9) 8.5 (3.9) 8.2 (2.8) 8.8 (4.1)
RAP, mmHg 4.6 (2.5) 4.6 (2.0) 4.6 (2.7) 4.4 (2.1) 4.7 (2.8)
PVR, WU 3.2 (1.6) 4.9 (1.6)*** 2.3 (0.8) 4.5 (1.5)** 2.1 (0.6)
Cardiac index, l/min/m2 3.1 (0.8) 2.9 (0.6) 3.2 (0.9) 2.9 (0.5) 3.2 (0.9)
CPET parameters
VO2/kg max, ml/min/kg 16.0 (4.0) 14.5 (4.3) 16.7 (3.9) 15.3 (4.5) 16.6 (3.9)
VO2/HR max, ml/b.p.m. 6.7 (1.5) 6.2 (1.9) 6.9 (1.5) 6.7 (2) 6.6 (1.4)
VE/VCO2@fVT 41.1 (7.4) 49.0 (5.5)*** 37.4 (4.8) 46.8 (6.3)*** 36.8 (4.8)
VE/VCO2 slope 38.7 (6.6) 45.3 (4.4)*** 35.7 (5.1) 43.4 (5.1)*** 35.2 (5.3)
PetCO2@fVT, mmHg 29.9 (4.6) 25.6 (2.6)*** 31.8 (3.9) 26.8 (3.3)*** 32.1 (4.1)
Echocardiographic parameters
LVEDV/BSA, ml/m2 50.6 (10.5) 49.3 (13.4) 51.2 (9.0) 49.0 (11.8) 51.7 (9.5)
LVEF, % 62.7 (7.3) 62.6 (6.7) 62.8 (7.7) 62.6 (6.7) 62.8 (7.9)
LAEDV/BSA, ml/m2 28.4 (10.6) 27.6 (12.1) 28.2 (9.9) 26.4 (12.5) 29.2 (10.2)
RA area, cm2 15.3 (3.4) 14.5 (3.9) 15.7 (3.2) 15.0 (3.8) 15.6 (3.2)
RV basal diameter, mm 35.1 (4.9) 33.9 (5.4) 35.7 (4.6) 33.6 (4.9) 36.2 (4.7)
Trjet vel max, cm/s 2.6 (0.5) 2.8 (0.7) 2.6 (0.4) 2.8 (0.7) 2.6 (0.4)
PacT, cm/s2 104.7 (27.8) 94.9 (31.4) 109.4 (25.0) 94.5 (29.5)* 112.5 (24.1)
TAPSE, mm 21.9 (3.5) 21.4 (3.4) 22.2 (3.5) 21.7 (2.9) 22.2 (3.9)
RV S’, cm/s 12.8 (2.9) 13.0 (3.8) 12.7 (2.4) 13.0 (3.3) 12.6 (2.6)
RV FAC, % 40.3 (9.0) 36.7 (8.7) 41.8 (8.8) 36.9 (8.3)* 42.7 (8.8)
IVC size >2.1 cm
or sniff variation
<50%, n (%)
1 (2) 1 (6) 0 1 (6) 0
*Values expressed as mean (S.D.) except NTproBNP, expressed as median (interquartile range). P < 0.05, **P < 0.01, ***P <
0.001. PAH+: SSc patients with pulmonary arterial hypertension; PAH: SSc without PAH; PC-PH+: patients with pre-capillary
pulmonary hypertension (PH); PC-PH: patients without PC-PH; FVC: forced vital capacity; DLCO: diffusing capacity for
carbon monoxide; mPAP: mean pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; RAP: right atrial
pressure; PVR: pulmonary vascular resistance; CPET: cardiopulmonary exercise testing; VE: minute ventilation (VE); VO2:
oxygen production; VCO2: carbon dioxide production; HR: heart rate; VE/VCO2@fVT: VE/VCO2 at the fVT; PetCO2@fVT:
low end-tidal CO2 pressure at fVT; LVEDV/BSA: left ventricular end-dyastolic volume per body surface area; LVEF: left-
ventricular ejection fraction; LAEDV/BSA: left atrium end-dyastolic volume per BSA; RA: right atrium; RV: right ventriculm;
Trjet vel max: peak velocity of the trans-tricuspid jet; RV S’: RV longitudinal myocardial velocity; PacT: pulmonary artery
acceleration time; TAPSE: tricuspidal anulus; FAC: fractional area change; IVC: inferior vena cava.
4 https://academic.oup.com/rheumatology
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SSc-PAH patients with high pulmonary vascular resist-
ance would increase the right ventricular afterload
during exercise and then enhance the dysregulation of
ventilatory control mechanisms via cardiac autonomic
reflex (Bainbridge reflex), eliciting a high VE/VCO2 slope
[13, 14]. Thus, the CPET may represent a valid physio-
logical assessment to stress the cardiopulmonary
system in SSc and to exhibit a hidden pulmonary vascular
involvement when right heart remodelling/overload is not
appreciable at US. Accordingly, in our population, echo-
cardiographic parameters did not differ between SSc pa-
tients with or without PAH (Table 1). Only 56% of our
patients would have been referred to RHC according to
the ESC/ERS criteria, missing four PAH (23.5%), confirm-
ing the rates of missed diagnoses reported in the DETECT
population (29%) [6]; expectedly, the performance of
ESC/ERS criteria were even worse when pre-capillary
PH was considered, with 8/23 (35%) missed diagnoses.
Albeit the physiopathological mechanisms described
above constitute a strong basis for the use of CPET in
SSc patients at risk for PAH/pre-capilalry PH and despite
the robust and extensive internal validation method we
used, the limited sample size and lack of an external
population to test the generalizability of our approach
are clear limitations of our study. Similarly, we cannot
make any inference about the validity of CPET coupled
with screening algorithms other than DETECT or in con-
junction with algorithms specifically optimized for pre-ca-
pillary PH. Moreover, due to the influence of left-heart
disease on CPET parameters, any strategy aimed at
excluding left-heart impairment would help to overcome
CPET limitations, further enhancing its significance in a
structured screening strategy. Despite these shortcom-
ings, CPET appears to be a promising, non-invasive tool
in the screening workup for SSc-related PH.
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